Brind.
  1. Kazia Therapeutics Limited is evaluating Paxalisib in combination regimens for advanced triple negative breast cancer through a Phase 1b trial.
  2. Kazia Therapeutics Limited announced clinical trial updates from Sydney on May 26, 2026.

Kazia Therapeutics' clinical trial utilizes Merck's Keytruda.

1 report, 1 independent Updated Jul 10
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Kazia Therapeutics' clinical trial utilizes Merck's Keytruda.

Who's involved

What this event is mainly about
Kazia Therapeutics (Australia)

Keep exploring

Part of

Kazia Therapeutics Limited announced clinical trial updates from Sydney on May 26, 2026. All 1 developments

Within Kazia Therapeutics Limited is evaluating Paxalisib in combination regimens for advanced triple negative breast cancer through a Phase 1b trial.

The entities involved

Coverage

Newest first; wire copies grouped
  • BenzingaKazia Reports Over 50% Cancer Cell Reduction In Early Data From Breast Cancer Trial, Stock Jumps Kazia Therapeutics (NASDAQ:KZIA) on Wednesday reported preliminary results from the first patient in i